Sugi Predict

Sugi Predict / Compounds / SCHEMBL4485052

SCHEMBL4485052

SCHEMBL4485052

CN(C(=O)C(C)(C)N)c1cccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2ccccc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 1/20 0.36
▸ PLK1 P53350 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ MAPT P10636 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ LRRK2 Q5S007 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KDR P35968 2/20 0.34
▸ CA12 O43570 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ PPARG P37231 2/20 0.33
▸ NR1H4 Q96RI1 2/20 0.33
▸ KCNK3 O14649 1/20 0.33
▸ KCNK9 Q9NPC2 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4500469 0.91 LRRK2 (0.35) RXFP1NPC1RAB9AMAPTMEN1
SCHEMBL4485403 0.90 LRRK2 (0.35) MEN1KMT2ALRRK2CA12CA2
SCHEMBL227304 0.86 KDR (0.36) PLK1NPC1RAB9ALRRK2KDR
SCHEMBL4485060 0.85 RXFP1 (0.37) RXFP1PLK1NPC1RAB9AMAPT
SCHEMBL4485055 0.85 RXFP1 (0.37) RXFP1PLK1NPC1RAB9AMAPT
SCHEMBL4504444 0.84 P2RX1 (0.40) RXFP1PLK1NPC1RAB9AMEN1
SCHEMBL4506120 0.83 LRRK2 (0.42) RXFP1PLK1NPC1RAB9AMAPT
SCHEMBL4481482 0.83 SENP1 (0.35) RXFP1NPC1RAB9AMAPTMEN1
SCHEMBL5856822 0.83 BACE1 (0.36) PLK1NPC1LRRK2KDRTGM2
SCHEMBL4493874 0.83 CASP3 (0.35) RXFP1PLK1MAPTLRRK2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 — — US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 — — US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 — — EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR RXFP1 425/4885PLK1 86/4885NPC1 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.